Tired of CPAP? FDA approval of Zepbound introduces new treatment for sleep apnea
The FDA approved Eli Lilly's Zepbound (tirzepatide) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, based on SURMOUNT-OSA trials showing significant reductions in apnea-hypopnea index (AHI) and substantial weight loss. Zepbound, which reduces appetite and food intake, offers a new non-invasive treatment option for OSA, a condition affecting 30 million Americans but significantly underdiagnosed. Common side effects include gastrointestinal issues, and patients with a history of medullary thyroid carcinoma should avoid the drug.
Highlighted Terms
Related News
The FDA approved Eli Lilly's Zepbound (tirzepatide) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, based on SURMOUNT-OSA trials showing significant reductions in apnea-hypopnea index (AHI) and substantial weight loss. Zepbound, which reduces appetite and food intake, offers a new non-invasive treatment option for OSA, a condition affecting 30 million Americans but significantly underdiagnosed. Common side effects include gastrointestinal issues, and patients with a history of medullary thyroid carcinoma should avoid the drug.